SMMT Q2 2022 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$235,000+312.3% YoY

Gross Profit

$193,05482.2% margin

Operating Income

-$13M-5400.9% margin

Net Income

-$17M-7136.6% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$96M

Total Liabilities

$44M

Stockholders' Equity

$51M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$235,000	$57,000	+312.3%
Gross Profit	$193,054	$57,000	+238.7%
Operating Income	-$13M	-$24M	+46.5%
Net Income	-$17M	-$24M	+31.3%

Revenue Segments

License and Service

$235,000100%

Geographic Segments

Latin America

$235,000100%